Core Insights - Three stocks with strong momentum and buy rankings are highlighted for investors: Gold Fields Limited, Genmab, and Aegon [1][2][3]. Group 1: Gold Fields Limited (GFI) - Gold Fields Limited is one of the world's largest unhedged gold producers with operations in South Africa, Ghana, and Australia [1]. - The company has a Zacks Rank 1 (Strong Buy) and its current year earnings estimate increased by 7% over the last 60 days [1]. - Gold Fields' shares gained 76.1% over the last three months, significantly outperforming the S&P 500's gain of 7% [2]. - The company possesses a Momentum Score of A [2]. Group 2: Genmab (GMAB) - Genmab is a biotechnology company specializing in antibody therapeutics for cancer treatment [2]. - The company also has a Zacks Rank 1 and its current year earnings estimate increased by 10.1% over the last 60 days [2][3]. - Genmab's shares gained 58.2% over the last three months, again outperforming the S&P 500's gain of 7% [3]. - The company possesses a Momentum Score of A [3]. Group 3: Aegon (AEG) - Aegon is an international insurance group providing life and health insurance, as well as pension, savings, and investment products in Europe, North America, and the Caribbean [3][4]. - The company has a Zacks Rank 1 and its current year earnings estimate increased by 10.1% over the last 60 days [3][4]. - Aegon's shares gained 11.1% over the last three months, outperforming the S&P 500's gain of 7% [4]. - The company possesses a Momentum Score of A [4].

Core Viewpoint - The article discusses the potential of the ALPS Medical Breakthroughs ETF (SBIO) as a strong investment option in the biotech sector, particularly in light of anticipated rate cuts that could benefit tech and biotech firms [1][6]. ETF Performance - The SBIO ETF charges a fee of 50 basis points and tracks a market cap-weighted index of biotech firms with drugs in Phase II or III clinical trials, focusing on companies with at least $200 million in AUM and up to $5 billion [2]. - SBIO has returned 16% over the last three months, outperforming its ETF Database Category average of 6.4% and FactSet Segment average of 7.4% [2]. Technical Indicators - The fund's price has surpassed both its 50 and 200-day simple moving averages, indicating healthy momentum and a potential buy signal [3]. Notable Holdings - Merus (MRUS) has shown significant performance, returning 59.6% year-to-date (YTD) as of September 11, focusing on clinical stage immuno-oncology [4]. - Akero Therapeutics (AKRO) has returned 55.4% YTD, developing treatments for serious metabolic diseases [5]. - Acadia Pharmaceuticals, Inc. (ACAD) has achieved a 29.7% return YTD, specializing in drugs for central nervous system disorders [5]. Market Environment - Rate cuts could facilitate borrowing for biotech firms while awaiting drug revenue, and may also ease M&A activity targeting these companies, making the biotech ETF a noteworthy investment in a lowering rate environment [6].

Core Points - Genmab A/S announced the retirement of Birgitte Stephensen, Executive Vice President and Chief Legal Officer, after 23 years with the company, effective July 1, 2025 [1][2] - Greg Mueller has been appointed as the new Executive Vice President, General Counsel, and Chief Legal Officer, effective July 1, 2025, and will report to the President and CEO, Dr. Jan van de Winkel [1][3] Company Overview - Genmab is an international biotechnology company focused on improving patient lives through innovative antibody therapeutics, with a vision to transform the lives of people with cancer and other serious diseases by 2030 [5] - Established in 1999 and headquartered in Copenhagen, Denmark, Genmab has a global presence across North America, Europe, and Asia Pacific [6]